French DNA data storage startup Biomemory has acquired the assets of Catalog Technologies, a Boston-based DNA computing and storage company.

The financial terms of the deal have not been disclosed, but in a statement, Biomemory said the purchase will support its aim of being the first DNA data storage provider to be deployed in data centers.

The new joint entity plans to launch its first commercial solution in the latter half of 2026, offering a “tangible, sustainable, and secure alternative” to traditional data storage media.

“Both technologies synergistically align, combining enzymatic bio-secure DNA blocks assembly with scalable high-speed printing, high-throughput reading, and a low error-rate,” the company said in a statement. “The transaction creates a unique and unrivaled combination of technology, expertise, hardware, and intellectual property under a single roof.”

The deal will also allow Paris-based Biomemory to establish a North American footprint, consisting of a flagship office in Boston to house R&D, production, and customer support efforts.

“This acquisition will allow Biomemory to design more compelling DNA data storage commercial solutions, progressively adding search and compute functions,” said Erfane Arwani, co-founder & CEO, Biomemory. “It is serving our ambition of a mass deployment in the IT and data center environment. One more step toward the global reach of Biomemory and a way to get closer to our North American customer base.”

Olivier Lauvray, VP of industrialization at Biomemory, added: “Biomemory is the first company in the DNA data storage industry to have implemented a complete end-to-end industrialized process. It spans the digital file or object ingestion to DNA writing and storage with a data retention of 50 to 150 years, and has the capability to access and read stored digital content all along the retention lifetime.”

Founded in 2021, Biomemory launched its DNA storage cards in December 2023. The cards work by converting digital information from binary code into the nucleotides that make up DNA – adenine (A), cytosine (C), guanine (G), and thymine (T), which can then be decoded by the company when the owner wants to access their data. Costing $1,000 and with a lifespan of up to 150 years, owners can store up to one kilobyte of DNA data on the credit card-sized storage device.

The following December, the company secured $18 million in a Series A funding round, with the funds used to complete the development of its first-generation data storage appliance, grow its workforce, and accelerate the commercialization of its offering.

Meanwhile, in 2022, Catalog Technologies encoded 200,000 words of eight Shakespeare tragedies into DNA and made the first step into DNA computation by demonstrating the ability to search for key query terms in the data.